Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
ACHV
ACHV
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ACHV News
Achieve Life Sciences Publishes New Study on Cytisinicline
5d ago
Newsfilter
Achieve Life Sciences Q4 2025 Earnings Call Insights
6d ago
seekingalpha
Iran Allows 'Non-Hostile' Vessels to Transit Strait of Hormuz
6d ago
seekingalpha
Achieve Life Sciences Q4 Earnings Miss Expectations
Mar 24 2026
seekingalpha
ACHIEVE LIFE SCIENCES INC REPORTS Q4 NET LOSS OF $14.7 MILLION, FY2025 NET LOSS TOTALS $54.7 MILLION
Mar 24 2026
moomoo
Achieve Life Sciences Set to Announce Q4 Earnings on March 24
Mar 23 2026
seekingalpha
Major Earnings Reports Expected Before Tuesday's Open: Xiaomi and More
Mar 23 2026
seekingalpha
Achieve Life Sciences Appoints Mark Rubinstein as Chief Medical Officer
Jan 12 2026
NASDAQ.COM
Achieve Life Sciences Submits NDA for Cytisinicline, Expected U.S. Launch in 2026
Dec 30 2025
Benzinga
Achieve Life Sciences to Host Investor Meetings at 2026 J.P. Morgan Healthcare Conference
Dec 17 2025
PRnewswire
Achieve Life Sciences Grants 250,000 Stock Options to New Chief Legal Officer
Dec 08 2025
Globenewswire
Citizens Begins Coverage of Achieve Life Sciences (ACHV) with a Positive Market Outlook
Nov 26 2025
NASDAQ.COM
Citizens Begins Coverage of Achieve Life Sciences with Market Outperform Rating and Sets Price Target at $19
Nov 25 2025
Benzinga
Achieve Life Sciences Awarded FDA Commissioner’s National Priority Voucher for Cytisinicline to Aid in E-cigarette and Vaping Addiction Treatment
Oct 17 2025
Newsfilter
Achieve, Disc, and Revolution Among Recipients of First FDA National Priority Vouchers
Oct 17 2025
SeekingAlpha
Achieve Life Sciences Publishes Data in Thorax Highlighting Cytisinicline's Potential Effectiveness and Tolerability for Smoking Cessation in COPD Patients
Sep 22 2025
Newsfilter
Show More News
